News

Publication of the 2024 Annual Financial Report 

30 April 2025


Paris and Boston, April 30, 2025 – 9:15 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that it has published its Annual Financial Report for the year ended December 31, 2024 and filed it with the Autorité des Marchés Financiers (AMF) on April 30, 2025. 

This report can be consulted on the Mauna Kea Technologies website, in accordance with current regulations. It can be consulted or downloaded at www.maunakeatech.com in the Investors > Financials, as well as on the AMF website (www.amf-france.org). 

*** 

Financial calendar: 

2025 Half-Year Financial Results on October 2, 2025, after market close 

Annual General Meeting on June 5, 2025 

READ THE COMPLETE PRESS RELEASE

Latest News

Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 

Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 

Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update 

Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update 

Mauna Kea Technologies announces entrance into exclusive negotiations for a licensing agreement for Cellvizio® in an important therapeutic area with a major industry player 

Mauna Kea Technologies announces entrance into exclusive negotiations for a licensing agreement for Cellvizio® in an important therapeutic area with a major industry player